We are monitoring the impact of COVID-19 on Europe Uterine Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Europe Uterine Cancer Therapeutics Market Research Report – Segmented By Type, Therapy, Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2022 to 2027)

Published: January, 2022
ID: 1412
Pages: 137

Europe Uterine Cancer Therapeutics Market Size (2022 to 2027)

The size of the Uterine Cancer Therapeutics Market in Europe is expected to be worth USD 8.2 Billion by 2027 from USD 6.32 Billion in 2022, growing at a CAGR of 5.34% during the forecast period.

Uterine cancer is a type of malignant tumor that starts in the uterus cells and spreads to other body areas. There are two kinds of uterine cancer: uterine sarcoma and endometrial carcinoma. As a result, more treatments for uterine cancer, such as surgery, chemotherapy, radiation therapy, immunotherapy, and hormone therapy, have become accessible. 

The European uterine cancer therapeutics market is projected to grow significantly due to increased healthcare expenditure and healthcare infrastructure facilities in the region. Furthermore, the Proliferation of the uterine cancer population and the growing awareness among people about uterine therapies are accelerating the market growth in Europe, also increasing the incidence of uterine cancer, and advancements in the molecular diagnostic industry support target-specific therapies. In addition, increasing investment and funding by the government and private organizations to develop healthcare services in the region is majorly influencing the market growth. 

Moreover, the rising focus of government initiatives for developing therapeutic cancer centers is encouraging market participants. Technological advancements in drugs and innovations regarding uterine cancer boost market growth in developed countries such as Germany, UK, and France. 

However, the high cost of the treatment solutions, limited access to advanced cancer therapies in some developing regions are expected to restrain the growth of the Uterine Cancer Therapeutics Market.

This research report on the European Uterine Cancer Therapeutics Market is segmented & sub-segmented into the following categories:

By Type:

  • Uterine Sarcoma
  • Endometrial Carcinoma
  • Adenocarcinoma
  • Carcinosarcoma
  • Squamous Cell Carcinoma
  • Others

By Therapy:

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Hormone Therapy

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, Europe is the second-largest region in terms of market revenue in the Uterine Cancer Therapeutics Market over the forecast period. The market is expected to account significant share during the forecast period. The region's market growth is attributed to the severity of the illness and the importance; healthcare professionals and governments are implementing awareness campaigns in certain regions. In addition, major companies in the area are investing in the research and development of therapeutic cancer centers. Rising importance on women's healthcare is the two major factors uplifting the market growth during the forecast period. In the regional market, the UK dominated the Uterine Cancer Therapeutics Market during the previous year. Factors such as an increase in women being diagnosed with uterine cancer across the UK influences market growth. Moreover, technological advancements in uterine cancer therapeutics provide lucrative opportunities for the market players to introduce new products.

On the other hand, countries such as Germany, France, Spain, and Italy are most likely to account highest market share and contribute to the regional market growth over the forecast period. This is because an increase in the incidence of uterine cancer population, growing awareness among the people, and rising healthcare expenditure are expanding the market in these countries.

KEY MARKET PLAYERS:

A few of the promising companies operating in the European Uterine Cancer Therapeutics market profiled in this report are Abbott Laboratories, Ariad Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Sanofi, Siemens Healthcare GmbH and Takeda Pharmaceutical Company Ltd.

1.Introduction              

                1.1 Market Definition

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods       

                1.4 General Study Assumptions                

2. Research Methodology   

                2.1 Introduction          

                2.2 Research Phases  

            2.2.1 Secondary Research            

            2.2.2 Primary Research 

            2.2.3 Econometric Modelling     

            2.2.4 Expert Validation  

                2.3 Analysis Design     

                2.4 Study Timeline      

3. Overview                  

                3.1 Executive Summary                

                3.2 Key Inferences     

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                  

                4.1 Market Drivers      

                4.2 Market Restraints

                4.3 Key Challenges     

                4.4 Current Opportunities in the Market               

5. Market Segmentation      

                5.1 By Type    

            5.1.1 Endometrial Carcinoma     

        5.1.2.1 Adenocarcinoma

        5.1.2.2 Carcinosarcoma

        5.1.2.3 Squamous cell carcinoma

        5.1.2.4 Others

            5.1.2 Uterine Sarcoma  

                5.2 By Therapy                 

            5.2.1 Surgery    

            5.2.2 Chemotherapy     

            5.2.3 Radiation Therapy

            5.2.4 Immunotherapy   

            5.2.5 Hormone Therapy

6. Geographical Analysis      

                6.1 Introduction          

                6.2 U.K                

                6.3 Spain         

                6.4 Germany 

                6.5 Italy           

                6.6 France      

7. Pipeline Product Analysis

                7.1 Overview

                7.2 Pipeline Development Landscape

                7.3 Molecular Targets in the Pipeline  

                7.4 Clinical Trials          

            7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

            7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

            7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis

                8.1 PESTLE analysis     

            8.1.1 Political     

            8.1.2 Economic 

            8.1.3 Social         

            8.1.4 Technological         

            8.1.5 Legal          

            8.1.6 Environmental      

                8.2 Porter’s Five analysis          

            8.2.1 Bargaining Power of Suppliers        

            8.2.2 Bargaining Power of Consumers    

            8.2.3 Threat of New Entrants     

            8.2.4 Threat of Substitute Products and Services

            8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis  

                9.1 Abbott Laboratories (U.S.)                   

            9.1.1 Overview

            9.1.2 Product Analysis   

            9.1.3 Financial analysis  

            9.1.4 Recent Developments       

            9.1.5 SWOT analysis       

            9.1.6 Analyst View          

                9.2 Ariad Pharmaceuticals, Inc. (U.S.) 

                9.3 Becton, Dickinson and Company (U.S.)       

                9.4 F. Hoffmann-La Roche AG (Switzerland)    

                9.5 GlaxoSmithKline Plc (U.K.)                   

                9.6 Merck & Co., Inc. (U.S.)     

                9.7 Novartis AG (Switzerland)

                9.8 Sanofi (France)     

                9.9 Siemens Healthcare GmbH (Germany)       

                9.10 Takeda Pharmaceutical Company Ltd. (Japan)      

10.Competitive Landscape  

                10.1 Market share analysis      

                10.2 Merger and Acquisition Analysis 

                10.3 Agreements, collaborations and Joint Ventures   

                10.4 New Product Launches   

11.Market Outlook & Investment Opportunities           

Appendix   

                a) List of Tables                

                b) List of Figures          

  1. Europe Uterine Cancer Therapeutics Market, By Region, From 2022 - 2027 (USD Million)
  2. Europe Uterine Cancer Therapeutics Market, By Type, From 2022 - 2027 (USD Million)
  3. Europe Endometrial Carcinoma Market, By Region, From 2022 - 2027 (USD Million)
  4. Europe Uterine Sarcoma Market, By Region, From 2022 - 2027 (USD Million)
  5. Europe Uterine Cancer Therapeutics Market, By Therapy, From 2022 - 2027 (USD Million)
  6. Europe Uterine Cancer Surgery Market, By Region, From 2022 - 2027 (USD Million)
  7. Europe Uterine Cancer Chemotherapy Market, By Region, From 2022 - 2027 (USD Million)
  8. Europe Uterine Cancer Immunotherapy Market, By Region, From 2022 - 2027 (USD Million)
  9. Europe Uterine Cancer Radiation Therapy Market, By Region, From 2022 - 2027 (USD Million)
  10. Europe Uterine Cancer Hormone Therapy Market, By Region, From 2022 - 2027 (USD Million)
  11. U.K. Uterine Cancer Therapeutics Market, By Type, From 2022 - 2027 (USD Million)
  12. U.K. Uterine Cancer Therapeutics Market, By Therapy, From 2022 - 2027 (USD Million)
  13. Germany Uterine Cancer Therapeutics Market, By Type, From 2022 - 2027 (USD Million)
  14. Germany Uterine Cancer Therapeutics Market, By Therapy, From 2022 - 2027 (USD Million)
  15. France Uterine Cancer Therapeutics Market, By Type, From 2022 - 2027 (USD Million)
  16. France Uterine Cancer Therapeutics Market, By Therapy, From 2022 - 2027 (USD Million)
  17. Italy Uterine Cancer Therapeutics Market, By Type, From 2022 - 2027 (USD Million)
  18. Italy Uterine Cancer Therapeutics Market, By Therapy, From 2022 - 2027 (USD Million)
  19. Spain Uterine Cancer Therapeutics Market, By Type, From 2022 - 2027 (USD Million)
  20. Spain Uterine Cancer Therapeutics Market, By Therapy, From 2022 - 2027 (USD Million)
  21. Europe Endometrial Carcinoma Market, By Type, From 2022 - 2027 (USD Million)
  22. Europe Adenocarcinoma Market, By Region, From 2022 - 2027 (USD Million)
  23. Europe Carcinosarcoma Market, By Region, From 2022 - 2027 (USD Million)
  24. Europe Squamous cell carcinoma Market, By Region, From 2022 - 2027 (USD Million)
  25. Europe Other Endometrial Carcinoma Market, By Region, From 2022 - 2027 (USD Million)
  26. U.K. Endometrial Carcinoma Market, By Type, From 2022 - 2027 (USD Million)
  27. Germany Endometrial Carcinoma Market, By Type, From 2022 - 2027 (USD Million)
  28. France Endometrial Carcinoma Market, By Type, From 2022 - 2027 (USD Million)
  29. Italy Endometrial Carcinoma Market, By Type, From 2022 - 2027 (USD Million)
  30. Spain Endometrial Carcinoma Market, By Type, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample